NeuBase(NBSE) - 2022 Q4 - Annual Report

Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the Transition Period from to Commission File Number 001-35963 NEUBASE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-5622433 (State or other j ...